Evidence map›Paper›PMID 30067789›Full record

ArticlePloS one2018

Advanced glycation end products (AGEs) estimated by skin autofluorescence are related with cardiovascular risk in renal transplant.

Jesus Calviño, Secundino Cigarran, Lourdes Gonzalez-Tabares, Nicolas Menendez, Juan Latorre, Sonia Cillero, Beatriz Millan, Carmen Cobelo, Ana Sanjurjo-Amado, Jansen Quispe and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Role of skin autofluorescence in managing renal and cardiac diseases in outpatient dermatology.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2022
    Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Jesus CalviñoNephrology, Hospital Lucus Augusti, Lugo, Spain.ORCID 0000-0003-3330-2673
Secundino CigarranNephrology, Hospital da Costa, Lugo, Spain.
Lourdes Gonzalez-TabaresNephrology, Hospital Lucus Augusti, Lugo, Spain.
Nicolas MenendezNephrology, Hospital da Costa, Lugo, Spain.
Juan LatorreNephrology, Hospital da Costa, Lugo, Spain.
Sonia CilleroNephrology, Hospital Lucus Augusti, Lugo, Spain.
Beatriz MillanNephrology, Hospital Lucus Augusti, Lugo, Spain.
Carmen CobeloNephrology, Hospital Lucus Augusti, Lugo, Spain.
Ana Sanjurjo-AmadoNephrology, Hospital da Costa, Lugo, Spain.
Jansen QuispeNephrology, Hospital Lucus Augusti, Lugo, Spain.
Alba Garcia-EnriquezNephrology, Hospital Lucus Augusti, Lugo, Spain.
Juan J CarreroDepartment of Medical Epidemiology and Biostatistics (MEB), Karolinska Institutet, Stockholm, Sweden.
Hospital Universitario Lucus Augusti · ESHospital Costa del Sol · ESKarolinska Institutet · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAdvanced glycation end products (AGEs) accumulation, a measure of cumulative metabolic stress, constitute a novel pathogenic mechanism involved in aging, diabetes, cardiovascular (CVD) and chronic kidney disease (CKD). Despite removal of uremic toxins and AGEs after a successful renal transplant (RT), CVD remains the leading cause of mortality. We hypothesized that AGEs measurement by Skin Autofluorescence (SAF) might be useful even after a successful RT and thus reflect the high cardiovascular risk burden of these patients.

methods189 stable RT (61% men, aged 56±13.0 years), CKD stages 1-4 and >12 months since RT were enrolled. Variables collected comprised comorbid history, medication use, smoking habit, routine biochemistry, subclinical atheromatosis by ankle-brachial-index (ABI) and allograft resistivity index (RI), 24-h ABPM, anthropometry and handgrip strength. AGEs were measured by SAF and expressed in arbitrary units (AU). Vascular age was estimated by Koetsier´s formula (SAF-0.83/0.024) and expected 10-years cardiovascular death risk was calculated with the REGICOR score.

resultsMean SAF was 3.00±0.83 AU and estimated vascular age 90±34.7 years (30 years above biological age). SAF was higher among men (3.10±0.91 vs 2.81±0.66), diabetic nephropathy (3.49±0.75 vs 2.96±0.83) and steroid users (3.14±0.86 vs 2.71±0.69). We observed a positive correlation of SAF with night-systolic blood pressure (r = 0.25, p = 0.001), parathormone (r = 0.20, p<0.01), phosphate (r = 0.28, p<0.001) and negative with hemoglobin (r = -0.29, p<0.001), CKD-EPI (r = -0.32, p<0.001), albumin (r = -0.17, p<0.05), and dynamometry (r = -0.20, p<0.01). Subclinical vascular atheromatosis (ABI and RI) as well as the REGICOR scale (r = 0.35 p<0.001) were also correlated with SAF. In multivariable analysis age, gender, steroid use, serum phosphate and handgrip strength remained independently associated with SAF.

conclusionsSAF levels are elevated in RT patients and correlate with CVD risk. Besides age and male sex, our results suggest that phosphate overload, steroid use and nutritional status are important factors linking to AGEs accumulation.

Indexed as

Kidney TransplantationOptical ImagingAdultAgedAged, 80 and overBiomarkersCardiovascular DiseasesFemaleGlycation End Products, AdvancedHumansMaleMiddle AgedPrognosisRenal Insufficiency, ChronicRisk FactorsSkinBiomarkersGlycation End Products, Advanced

Identifiers

PMID30067789
PMCPMC6070236
OpenAlexW2886889919

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.